Sarepta Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	235.24	-535.98	-703.49	-418.78
Depreciation & Amortization	37.72	44.4	41.86	38.02
Loss (Gain) From Sale of Assets	-	-102	-	-102
Loss (Gain) From Sale of Investments	-	30.32	2.58	4.39
Stock-Based Compensation	184.3	182.51	233.02	113.94
Other Operating Activities	53.56	360.84	140.16	19.43
Change in Accounts Receivable	-201.66	-185.7	-61.64	-51.65
Change in Inventory	-395.17	-147.71	-50.78	-83.77
Change in Accounts Payable	110.65	-50.14	147.57	23.3
Change in Unearned Revenue	-32.16	-86.83	-89.24	-89.24
Change in Other Net Operating Assets	-198.26	-10.71	14.62	103.2
Operating Cash Flow	-205.79	-500.99	-325.35	-443.17
Capital Expenditures	-136.96	-76.11	-30.82	-38.49
Sale (Purchase) of Intangibles	-10	90.76	-1.43	99.69
Investment in Securities	902.52	-180.46	-1,015	434.21
Investing Cash Flow	755.56	-165.8	-1,047	495.41
Long-Term Debt Issued	-	-	1,127	-
Long-Term Debt Repaid	-0.07	-	-823.23	-
Net Debt Issued (Repaid)	-0.07	-	304.17	-
Issuance of Common Stock	79.53	51.25	30.04	569.33
Repurchase of Common Stock	-	-	-	-7.77
Other Financing Activities	45.35	73.76	-101.7	-
Financing Cash Flow	124.81	125	232.51	561.57
Net Cash Flow	674.58	-541.79	-1,140	613.81
Free Cash Flow	-342.74	-577.1	-356.17	-481.66
Free Cash Flow Margin	-18.02%	-46.41%	-38.17%	-68.62%
Free Cash Flow Per Share	-3.18	-6.25	-4.07	-5.93
Cash Interest Paid	15.86	15.92	44.42	55.95
Cash Income Tax Paid	22.59	15.08	1.7	0.58
Levered Free Cash Flow	-445.48	-330.11	-54.65	-8.7
Unlevered Free Cash Flow	-433.99	-316.36	-21.37	31.01
Change in Working Capital	-716.61	-481.09	-39.47	-98.17

Source: S&P Global Market Intelligence. Standard template. Financial Sources.